OPK Showing Recent Insider Activity
Recent activity shows that Opko Health, OPK the Insider Confidence level is trending Up due to Corporate Insiders of OPK Bought $2.4M worth of shares in the last 3 months.Before you dig into this report it is important to remember that "Insider Buying" is the purchase of shares in a corporation by a director, officer, or executive within the company. Insider buying is not the same as insider trading, which refers to corporate insiders making illegal stock purchases based on non-public information.
"Insider Buying" is not a crime when the buying is based on public information.
Additionally, since insiders have unique insights into their own companies, they often gobble up shares when they believe the stock is undervalued or dump stock when it’s time to sell. That's why people pay attention to insider buying.
- Phillip Frost - CEO & Chairman,Director,>10% Owner, Bought $94,770 worth of shares on 4 days ago
- Phillip Frost - CEO & Chairman,Director,>10% Owner, Bought $92,287 worth of shares on 1 day ago
- Phillip Frost - CEO & Chairman,Director,>10% Owner, Bought $95,364 worth of shares on 5 days ago
- Phillip Frost - CEO & Chairman,Director,>10% Owner, Bought $96,815 worth of shares on 6 days ago
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook.
Opko Health, OPK
Summary: OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.
- Last Price: $1.86
- Price Change: $0.05, 2.76%
- Yearly Gain: -51.34%
- Market Cap: $1.40B
- P/E Ratio: -6.118
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
When an OPK analyst reiterates coverage on stocks, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to OPK, you should consider joining TipRanks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================